1. Transurethral seminal vesiculoscopy for recurrent hemospermia: experience from 419 cases
- Author
-
Huizhen Li, Zhi-Yong Liu, Depei Kong, Zhen-Yu Jia, Sheng Xia, Lei Wang, Yinghao Sun, Chun-Lei Zhang, Xinwen Nian, Guanghua Chen, Tie Zhou, Yawei Liu, Guang-An Xiao, Xin Lu, Xin Cheng, Shu-Guang Piao, and Rui Chen
- Subjects
Male ,medicine.medical_specialty ,Urology ,transurethral seminal vesiculoscopy ,Treatment outcome ,030232 urology & nephrology ,Ejaculatory duct ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Seminal tract ,endoscopy ,030219 obstetrics & reproductive medicine ,medicine.diagnostic_test ,business.industry ,Mucosal lesions ,Seminal Vesicles ,Hemospermia ,General Medicine ,medicine.disease ,Surgery ,Endoscopy ,Clinical trial ,Ejaculatory Ducts ,Stenosis ,medicine.anatomical_structure ,Original Article ,business - Abstract
We summarized our experience in transurethral seminal vesiculoscopy (TSV) for recurrent hemospermia by introducing surgical techniques, intraoperative findings, and treatment outcomes. TSV was performed in 419 patients with an initial diagnosis of persistent hemospermia at Shanghai Changhai Hospital (Shanghai, China) from May 2007 to November 2015. TSV was successfully performed in 381 cases (90.9%). Hemospermia was alleviated or disappeared in 324 (85.0%) patients by 3 months after surgery. Common intraoperative manifestations were bleeding, obstruction or stenosis, mucosal lesions, and calculus. Endoscopic presentation of the ejaculatory duct orifice and the verumontanum was categorized into four types, including 8 (1.9%), 32 (7.6%), 341 (81.4%), and 38 (9.1%) cases in Types A, B, C, and D, respectively. TSV is an effective and safe procedure in the management of seminal tract disorders. This study may help other surgeons to become familiar with and improve this procedure. However, further multicentric clinical trials are warranted to validate these findings.
- Published
- 2018